Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.

Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised. IVT will manage and optimize vaccine manufacturing and distribution in partnership with global leaders in peptide manufacturing.